The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

The Medicines Company MDCO announced today that the global license and two-year collaboration for Recothrom(R), a recombinant thrombin approved by the U.S. Food and Drug Administration for use as a topical hemostat to control non-arterial bleeding during surgical procedures, established with Bristol-Myers Squibb Company BMY has become effective. The agreement was first announced in December 2012. The companies have satisfied all required regulatory and closing conditions.